NanoLogix Inc. to Exhibit at The American Society for Microbiology (ASM) General Meeting in Philadelphia; Announces Two New Pate
May 05 2009 - 8:45AM
PR Newswire (US)
HUBBARD, Ohio, May 5 /PRNewswire-FirstCall/ -- NanoLogix, Inc.
(Pink Sheets: NNLX) NanoLogix personnel will display the company's
BNP(TM) rapid-detection technology at booth 749 during the 109th
Annual ASM Meeting to be held at the Pennsylvania Convention Center
in Philadelphia May 17th - 21st. The ASM meeting is the world's
premier event for microbiology development. Representing NanoLogix
will be Dr. Sergey Gazenko and CEO Bret Barnhizer. Exhibition
information can be found at http://gm.asm.org/ NanoLogix recently
received two patents. United States patent number 7,524,623 was
granted for a "Method and device for rapid detection of
microorganisms by changing the shape of micro-colonies" and is the
first patent granted the company for BNC(TM) rapid-detection
technology. Christopher Novak, NanoLogix Director of Intellectual
Property said, "The issuance of the first US patent for the
BioNanoChannel(TM) (BNC) this past week is a very significant
development for NanoLogix. This patent provides NanoLogix with
substantial intellectual property protection for their
revolutionary rapid-detection technology. This greatly strengthens
NanoLogix's patent portfolio with additional patents anticipated in
the family of patent applications on file for this technology."
BNP(TM) and BNC(TM) are two distinct micro-biological
rapid-detection technologies developed by NanoLogix. The BNP is a
sandwiched-membrane, Petri-based system, that provides users the
ability to view microorganism cultures up to four times faster than
possible with traditional Petri techniques. The BNC is also a
unique development in rapid detection. It utilizes disks the size
of a quarter, each containing over two-million channels, to trap
microorganisms for identification and culturing. Both BNP and BNC
technologies offer the potential for reducing time-to-detection by
significant amounts when contrasted with current methods in
widespread use. United States patent number 7,473,552 for the
"Production of hydrogen gas and isolation of hydrogen producing
microorganisms using replenishing coated substrates" was also
recently received. The company adds this patent to their existing
archived hydrogen-related research portfolio. About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on medical
diagnostics. Its products offer accelerated detection and
identification of microorganisms present in infectious and
non-infectious human diseases, such as tuberculosis, NTM,
pneumonia, HIV/AIDS, cancer, cystic fibrosis, anthrax, and plague.
In addition to medical, Defense, and homeland security
applications, NanoLogix technology is applicable in pharmaceutical,
industrial, veterinary and environmental testing. Patents granted
to NanoLogix can be used in the areas of applied microbiology, soil
microbiology and bioremediation, microbial physiology, molecular
biology, pharmacology, pharmaco-kinetics, antibiotic sensitivity,
stem-cell research, and bioreactor-based hydrogen generation. More
information on NanoLogix is available at: http://www.nanologix.com/
This press release contains statements, which may constitute
"forward- looking statements" within the meaning of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended by
the Private Securities Litigation Reform Act of 1995. Those
statements include statements regarding the intent, belief or
current expectations of NanoLogix, Inc., and members of its
management as well as the assumptions on which such statements are
based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, and that actual results may
differ materially from those contemplated by such forward-looking
statements. The Company undertakes no obligation to update or
revise forward-looking statements to reflect changed assumptions,
the occurrence of unanticipated events or changes to future
operating results. Contact: NanoLogix, Inc. Investor Relations
Carol Surrena Telephone: 330-534-0800 E-mail: DATASOURCE:
NanoLogix, Inc. CONTACT: Carol Surrena, Investor Relations,
NanoLogix, Inc., +1-330-534-0800, Web Site:
http://www.nanologix.com/
Copyright